A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Alexey V. Danilov, Andy Kaempf et al.|Blood Advances|2023Cited by 49
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, David Qualls et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Jennifer Santos, Jason T. Romancik, Loretta J. Nastoupil et al.|UNC Libraries|2024Cited by 0
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortiumChijioke Nze, Narendranath Epperla, Allison M. Bock et al.|Blood|2025Cited by 0